72 related articles for article (PubMed ID: 34605897)
1. Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Rheumatology (Oxford); 2022 May; 61(6):2346-2359. PubMed ID: 34605897
[TBL] [Abstract][Full Text] [Related]
2. Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.
Sugawara M; Kojima S; Hisatome I; Matsui K; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Mori H; Tsujita K; Ohya Y; Kimura K; Saito Y; Ogawa H;
Clin Pharmacol Ther; 2024 Jun; 115(6):1358-1364. PubMed ID: 38389505
[TBL] [Abstract][Full Text] [Related]
3. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia: A real-world multicenter retrospective study.
Si X; Huang L; Ding Q; Zhang W; Zhao R; Ai C; An Z; Liu G; Zhang C; Zhong X; Feng Y
Medicine (Baltimore); 2024 Jan; 103(4):e37081. PubMed ID: 38277524
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials.
Yang XH; Zhang BL; Cheng Y; Fu SK; Jin HM
Ann Med; 2024 Dec; 56(1):2332956. PubMed ID: 38738384
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial.
Liu S; Lin X; Tao M; Chen Q; Sun H; Han Y; Yang S; Gao Y; Qu S; Chen H
Lipids Health Dis; 2024 Mar; 23(1):77. PubMed ID: 38468241
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout.
Sun W; Zhao X; Dalbeth N; Terkeltaub R; Cui L; Liu Z; Han L; Wang C; Zhang H; Bao Y; Li C; Lu J
J Inflamm Res; 2024; 17():2657-2668. PubMed ID: 38707960
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Serum Uric Acid and Exercise Capacity in Older Adults Hospitalized for Worsening Cardiovascular Disease.
Hirashiki A; Shimizu A; Kamihara T; Kokubo M; Hashimoto K; Ueda I; Murohara T
J Cardiovasc Dev Dis; 2024 May; 11(6):. PubMed ID: 38921665
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K; Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Hypertens Res; 2023 Jun; 46(6):1417-1422. PubMed ID: 36750608
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Saag KG; Becker MA; White WB; Whelton A; Borer JS; Gorelick PB; Hunt B; Castillo M; Gunawardhana L;
Arthritis Rheumatol; 2022 Sep; 74(9):1593-1601. PubMed ID: 35536764
[TBL] [Abstract][Full Text] [Related]
11. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Kataoka H; Mochizuki T; Ohara M; Tsuruta Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Kimura K; Hosoya T;
Sci Rep; 2022 Mar; 12(1):3784. PubMed ID: 35260678
[TBL] [Abstract][Full Text] [Related]
12. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
[TBL] [Abstract][Full Text] [Related]
13. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W
Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221
[TBL] [Abstract][Full Text] [Related]
14. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Yang N; Cao B
J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976
[TBL] [Abstract][Full Text] [Related]
15. Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.
Kusunose K; Yoshida H; Tanaka A; Teragawa H; Akasaki Y; Fukumoto Y; Eguchi K; Kamiya H; Kario K; Yamada H; Sata M; Node K;
Hypertens Res; 2022 Jan; 45(1):106-115. PubMed ID: 34657137
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications.
Anders HJ; Li Q; Steiger S
Clin Kidney J; 2023 Jun; 16(6):928-938. PubMed ID: 37261000
[TBL] [Abstract][Full Text] [Related]
17. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M; Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Int J Cardiol; 2022 Feb; 349():127-133. PubMed ID: 34864084
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Mar; 60(3):159-166. PubMed ID: 34779393
[TBL] [Abstract][Full Text] [Related]
19. Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial.
Jia E; Zhu H; Geng H; Wang Y; Zhong L; Liu S; Lin F; Zhang J
Trials; 2021 Oct; 22(1):743. PubMed ID: 34702311
[TBL] [Abstract][Full Text] [Related]
20. The relation between uric acid level and blood pressure values among patients hospitalized in a department of internal medicine.
Szydlik J; Nieznański J; Bałażyk K; Pokrzywnicki J; Sawicka A; Jankowski P
Postepy Kardiol Interwencyjnej; 2023 Jun; 19(2):142-151. PubMed ID: 37465626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
